Israeli Blood Test Accurately Detects Early Breast Cancer and Predicts Recurrence Risk

Scientists have developed an epigenetic blood test that distinguishes early-stage breast cancer from healthy samples and predicts recurrence risk.

Breast cancer remains the world’s most commonly diagnosed cancer among women, with approximately 2.3 million new cases recorded worldwide in 2022. Researchers from the Weizmann Institute of Science in Rehovot and the Hebrew University of Jerusalem have introduced a novel diagnostic tool that measures chemical modifications on cell-free nucleosomes using less than one milliliter of plasma.

The study, published in the peer-reviewed journal Nature, demonstrates high diagnostic accuracy and sheds light on why certain hormone-sensitive tumors display aggressive behaviors.

Researchers Identify Basal-Like Profiles in Luminal Breast Cancer

Led by Professor Efrat Shema of the Weizmann Institute and Professor Guy Ron of the Hebrew University, alongside Dr. Noa Furth, the research team focused on luminal breast cancer. This variant typically features receptors for estrogen or progesterone that fuel growth.

By analyzing 12 surgically removed, untreated tumors through single-cell analysis, the investigators identified distinct cell populations carrying a basal-like profile characterized by reduced hormone-receptor signaling and an increased ability to migrate.

Israeli Blood Test Accurately Detects Early Breast Cancer and Predicts Recurrence Risk
Photo: All Israel News

“The differences appear to be mainly epigenetic,” Shema said, referring to chemical changes that affect gene function without altering the underlying DNA sequence. In laboratory models, she explained, an aggressive population always emerged eventually.

To track these patterns in the bloodstream, the team adapted EPINUC, a technology that analyzes cell-free nucleosomes—DNA fragments wrapped around proteins released when cells die. Using single-molecule microscopy and fluorescent labels, the method measures dozens of epigenetic markers across millions of nucleosomes.

Testing 77 women with luminal breast cancer and 30 healthy women, the diagnostic model successfully distinguished cancer samples from healthy participants. When expanded to an evaluation group of 188 patient samples collected with the assistance of Sheba and Kaplan medical centers, a machine learning model trained on 75 percent of the data and tested on the remaining 25 percent achieved an area under the curve (AUC) of 0.96.

A separate set of samples from the Mayo Clinic produced an AUC of 0.98. The AUC measures how accurately a test distinguishes between two groups, where 1.0 represents perfect discrimination and 0.5 indicates performance no better than chance.

The blood test demonstrated strong diagnostic performance regardless of breast density. “Routine mammograms reduce the risk of dying from the disease by 22%, but the denser the breast tissue, the more likely a tumor is to ‘hide’ in the image,” Shema said.

In women with extremely dense breast tissue, conventional mammography screening sensitivity has been reported at around 50 percent in some studies, making complementary blood-based diagnostics a vital area of clinical investigation.

Israeli Blood Test Accurately Detects Early Breast Cancer and Predicts Recurrence Risk
Photo: Ynetnews

Assessing Recurrence Risk Beyond Conventional Measures

Even when breast cancer is diagnosed early and treatment appears successful, the disease returns in 20 percent to 40 percent of cases. To investigate this phenomenon, the researchers evaluated whether blood-based epigenetic patterns could predict relapse.

In the Mayo Clinic group, which incorporated five years of follow-up data, a predictive model achieved an AUC of 0.81, outperforming traditional prognostic factors such as cancer stage, tumor grade, and histological subtype. A smaller, separate patient cohort yielded an AUC of 0.92.

“When we searched the blood samples for the epigenetic signature of the aggressive cell population we had identified in the tumors, we found that the more prevalent this signature was, the greater the risk of the disease returning,” Ron said.

The test successfully identified an elevated risk of recurrence in patients who were classified as low-risk by conventional clinical assessments. “Evidence is mounting that cancer cells exploit their epigenetic flexibility to change, become more aggressive and evade treatment,” Shema said.

How Liquid Biopsy Analyzes Nucleosomes to Predict Recurrence

  • Liquid Biopsy Mechanism: The test analyzes cell-free nucleosomes—tiny DNA and protein fragments shed into the blood by dying cells—using less than one milliliter of plasma.
  • Overcoming Dense Tissue Limitations: Unlike conventional mammography, which can struggle to detect tumors hidden in dense breast tissue, this epigenetic blood test maintains high diagnostic performance across varying tissue densities.
  • Prognostic Precision: By identifying epigenetic signatures associated with aggressive, basal-like cells, the assay predicts recurrence risk more accurately than traditional tumor grading and staging alone.
Cohort / Model Group Sample Size (N) Diagnostic / Predictive Metric (AUC)
Expanded Multicenter Cohort (Sheba / Kaplan / Mayo) 188 breast cancer patients AUC 0.96 (Trained model); AUC 0.98 (Mayo set)
Mayo Clinic Recurrence Follow-Up Cohort Subset with 5-year follow-up AUC 0.81 (Relapse prediction)
Secondary Recurrence Validation Group Smaller separate cohort AUC 0.92 (Relapse prediction)

Why Experimental Tests Cannot Replace Routine Screening

While the EPINUC technology represents a promising advancement in molecular oncology, it remains an investigational method. The researchers emphasize that further clinical trials and extensive validation studies are required before the assay can be integrated into routine clinical practice. Patients should not rely on experimental blood tests as a standalone diagnostic replacement for established screening protocols such as mammography, clinical breast exams, and tissue biopsies.

Individuals experiencing persistent physical symptoms—such as new breast lumps, skin dimpling, nipple retraction, or unexplained axillary lymphadenopathy—should immediately consult a qualified physician or oncologist. Conventional diagnostic evaluations remain the gold standard for clinical decision-making and therapeutic intervention.

References

  • Shema, E., Ron, G., Furth, N. et al. (2026). Epigenetic heterogeneity in breast tumours informs diagnosis and prognosis. Nature. Nature Article DOI
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Arsenal Target Vinícius Júnior and Nico Paz in Summer Transfer Push

Elmore’s Book Explores Ireland’s Quirky Place Names